Sign In
Buy BIIB
$207.94
+1.66 (+0.80%)
At Close: Aug 07, 2026
Biogen Stock Moves Lower Despite Beat-and-Raise
10:21am, Wednesday, 20'th Jul 2022
Biogen Inc (NASDAQ: BIIB ) earlier lifted its full-year profit forecast after reporting blowout second-quarter profits of $5.25 per share on revenue of $2.59 billion, both of which came in above Wal
Biogen Inc. (BIIB) Q2 Earnings and Revenues Surpass Estimates
10:08am, Wednesday, 20'th Jul 2022
Biogen Inc. (BIIB) delivered earnings and revenue surprises of 28.36% and 4.69%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Biogen's stock is down 2.8% after missing on revenue in the second quarter
07:45am, Wednesday, 20'th Jul 2022
Shares of Biogen Inc. were down 2.8% in premarket trading on Wednesday after the company missed on revenue in the second quarter of the year. Revenue for three of Biogen's top-selling therapies - m
Netflix, Tesla, Biogen, and More of Wednesday's Stock Market Movers
07:18am, Wednesday, 20'th Jul 2022
Netflix lost 970,000 global subscribers in the second quarter, much better than its projection for a loss of 2 million. The stock is rising Wednesday.
Biogen profit more than doubles on Samsung Bioepis stake sale
07:14am, Wednesday, 20'th Jul 2022
(Reuters) -Biogen Inc on Wednesday posted second-quarter profit that more than doubled, driven by a roughly $1.5-billion gain from the sale of its equity stake in the Samsung Bioepis Joint Venture.
Analyst Ratings for Biogen
09:06pm, Monday, 18'th Jul 2022 Benzinga
Analysts have provided the following ratings for Biogen (NASDAQ:BIIB) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
0
5
1
0
0
Last 30D
Will Biogen (BIIB) Succeed in Beating Q2 Earnings Estimates?
03:10pm, Monday, 18'th Jul 2022 Zacks Investment Research
Biogen's (BIIB) multiple sclerosis revenues have been declining since the past few quarters. It is unlikely that MS sales have improved in the second quarter.
Will Biogen (BIIB) Succeed in Beating Q2 Earnings Estimates?
12:24pm, Monday, 18'th Jul 2022
Biogen's (BIIB) multiple sclerosis revenues have been declining since the past few quarters. It is unlikely that MS sales have improved in the second quarter.
J&J (JNJ) to Begin Pharma Sector's Q2 Earnings With a Beat?
12:17pm, Friday, 15'th Jul 2022 Zacks Investment Research
J&J's (JNJ) Pharma segment is expected to have performed above the market. In the MedTech segment, the recovery in demand trends seen in the first quarter is likely to have continued in the second.
Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: Should You Buy?
02:00pm, Wednesday, 13'th Jul 2022 Zacks Investment Research
Biogen Inc. (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: Should You Buy?
11:32am, Wednesday, 13'th Jul 2022
Biogen Inc. (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biogen Is Starting To Trend Higher (Technical Analysis)
03:19pm, Monday, 11'th Jul 2022
Biogen is beginning to have a trend change. Biogen is at the bottom of a trading range that goes back 10 years.
Stock Split Watch: Could Regeneron Be Next?
10:30am, Monday, 11'th Jul 2022 The Motley Fool
It's the highest-priced biotech stock.
How to fix the too-high 2022 Medicare Part B premium?
03:59pm, Friday, 08'th Jul 2022 MarketWatch
Midyear reductions and refunds don’t work; savings will be reflected in 2023 premium
7 Moonshot Investments Upending a $10 Trillion Industry
03:53pm, Friday, 08'th Jul 2022
Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future. The post 7 Moonshot Investments Upending a $10 Trillion Industry appeared first on
